Genmab (GMAB)

2,199.0
-43.0(-1.92%)
  • Volume:
    29,238
  • Bid/Ask:
    0.0/0.0
  • Day's Range:
    2,180.0 - 2,232.0
  • Type:Equity
  • Market:Denmark
  • ISIN:DK0010272202
  • S/N:65734141

GMAB Overview

Prev. Close
2,242
Day's Range
2,180-2,232
Revenue
9.02B
Open
2,216
52 wk Range
1,863-3,124
EPS
35.99
Volume
29,238
Market Cap
144.31B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
133,430
P/E Ratio
62.30
Beta
1.34
1-Year Change
-14.23%
Shares Outstanding
65,447,558
Next Earnings Date
09 Aug 2022
What is your sentiment on Genmab?
or
Vote to see community's results!

Genmab News

Genmab Company Profile

Genmab Company Profile

Employees
1136
Market
Denmark

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyNeutralNeutral
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong BuyStrong Sell
SummaryStrong BuyStrong BuyNeutralBuySell